Soleno Therapeutics (SLNO) Gross Profit: 2013-2017
Historic Gross Profit for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -$41,000.
- Soleno Therapeutics' Gross Profit rose 16.33% to -$41,000 in Q2 2017 from the same period last year, while for Jun 2017 it was $6,482, marking a year-over-year decrease of 94.25%. This contributed to the annual value of -$231,000 for FY2024, which is N/A change from last year.
- Per Soleno Therapeutics' latest filing, its Gross Profit stood at -$41,000 for Q2 2017, which was down 173.21% from $56,000 recorded in Q1 2017.
- Soleno Therapeutics' 5-year Gross Profit high stood at $191,000 for Q3 2015, and its period low was -$2.3 million during Q4 2014.
- For the 3-year period, Soleno Therapeutics' Gross Profit averaged around $19,827, with its median value being -$5,000 (2015).
- In the last 5 years, Soleno Therapeutics' Gross Profit crashed by 647.87% in 2014 and then spiked by 504.19% in 2016.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Gross Profit stood at -$310,267 in 2013, then crashed by 647.87% to -$2.3 million in 2014, then skyrocketed by 99.34% to -$15,211 in 2015, then skyrocketed by 504.19% to $61,482 in 2016, then climbed by 16.33% to -$41,000 in 2017.
- Its last three reported values are -$41,000 in Q2 2017, $56,000 for Q1 2017, and $61,482 during Q4 2016.